Think big

Webinar Replay: Exploring Porous Glass as a Cutting-Edge Substrate for Life Science Applications

Watch this groundbreaking webinar and dive into the transformative world of porous glass from enhancing DNA synthesis to superior filtration and explore the limitless possibilities that porous glass brings to the forefront of scientific advancements.

In this webinar, Dr. Bill James, PhD, will share an innovation in porous glass, SCHOTT CoralPor®, that has broad applications across life science. Porous glass can be used as a substrate to improve DNA synthesis, serve as a superior alternative to standard nitrocellulose membranes for filtration or separation, carry liquids more efficiently and more. Utilization has even extended further into an innovative application space: point-of-care (POC) diagnostics.

Register Now button

Topics in this presentation include:

  • Versatile applications of porous glass
  • Availability, properties and chemistry of porous glass
  • Innovative advancements in porous glass and how it contributes to superior performance metrics in the realm of point-of-care (POC) diagnostics

James Downs
Business Development Manager, US
Leveraging a rich 20+ year international career across a spectrum of the biopharmaceutical and medical device chains, James is passionate about exploring innovative solutions to help companies that are developing highly complex point-of-care and clinical diagnostic cartridges and components. James’ background includes a B.S. in Economics from the Univ. of Southern MS and an MBA and PhD in Economics from HHL Leipzig Graduate School of Business. His career spans management roles with Pfizer Inc, leading multiple medical device startups and now SCHOTT MINIFAB where is his responsible for business development

Bill James
VP of R&D and New Ventures, SCHOTT MINIFAB North America

Bill James completed his BS and PHD degrees in Chemistry from the University of Scranton and Purdue University, respectively. His doctoral dissertation research studied single-confirmation spectroscopy of foldamers. He expanded on this work by applying his physical chemistry expertise to his post-doctoral research on molecular conformations in supersonic expansions.
Bill’s career at SCHOTT North America began as a Product Development Scientist contributing new products across multiple application spaces. He worked his way through several promotions to become Vice President of the Research and Development and New Ventures team. His current responsibilities also include strategy development and program management for the US growth program and government relations.

Register Now button

Preserving capital: The Smart Strategy for Diagnostic and Life Science Companies

Written by Patrick Tuohy
Business Development Manager at SCHOTT MINIFAB

The past 3-4 years have been a roller coaster for everyone. Just when we started to see the light at the end of the tunnel from the global pandemic, we were hit with a cost-of-living crisis which we are still navigating through today. Diagnostic and Life Science companies are no different. While a massive influx of capital investments were the norm during the pandemic, the opposite is now true as venture funding has weakened. While there are more positive signs ahead in 2024, one thing is certain: a company’s capital is more important than ever, and it needs to be used efficiently.

Companies trying to get their product on the market are in a constant tug of war trying to get a product that is high quality, low cost and do this as quickly as possible. In parallel it needs to focus on:

  • Sales & Marketing activities to ensure the product is successful and maximize market reach.
  • R&D to maintain a pipeline of products that leverage the core technology, this can take the form of expanded test menus and/or product enhancements.

Purpose built Capabilities are key

SCHOTT MINIFAB are experts in the development and manufacture of microfluidic and microarray products for life science and diagnostic companies. To put it another way, life science and diagnostic companies can leverage our capabilities to preserve their capital. How?

  • Reduce Investments in Facilities & Capital Equipment: The Pilot Line capability at SCHOTT MINIFAB can be used to produce, assemble, and package our client’s microfluidic device. This avoids the need for companies to invest in building, maintaining, and upgrading production facilities and purchasing the complex manufacturing equipment required to produce a microfluidic device.
  • Reduce Per Capita Cost (both rate of and duration): Our clients product gets on the market sooner by leveraging the validated facilities and equipment at SCHOTT MINIFAB which are in place, and ready to go. SCHOTT MINIFAB have the experience and expertise to integrate complex manufacturing processes to produce our client’s devices: injection molding, bonding, reagent formulation, quality and supply chain (to name a few). These costs are shared across a portfolio of products which reduces costs to our client vs. going it alone, again allowing our clients to save valuable time and resources and to focus on their core technology, sales and marketing activities.
  • Breadth of Scale: SCHOTT MINIFAB have the capabilities to partner with our clients through the entire development and product life cycle, from the first 100 integrated prototypes to support first end to end tests, the first 10,000 products at market launch to the first 1,000,000 products produced on a fully automated line. This avoids the need to change suppliers as our clients navigate from development to manufacturing which reduces complexity and saves both time and money in tech transfer processes.

Benefits of outsourcing vs. in-house approach

This all sounds great right? Sign me up! But as companies compare outsourcing alternative approaches, such as doing it internally, there are some valid counter arguments.

It seems more expensive than if we were to do this internally: This is an easy assumption to make when taking a helicopter view, but when one ‘gets into the weeds’ this assumption quickly comes undone. Some of the key reasons for this are:

  • Capability Development: The time and cost associated with developing a capability is much greater than the time and cost it takes to purchase the equipment (knowledge development, labor, equipment & facilities). SCHOTT MINIFAB has spent decades investing in R&D to perfect processes required to produce high quality microfluidic devices. Developing capabilities in parallel to introducing a product on the market can have big cost and time implications. Piece prices can be very high with lower-than-expected yield and throughput which require excessive quality control processes to accommodate processes with poor capability.
  • Administration Costs: The HR and management costs required to coordinate, train, and sustain a manufacturing team often get overlooked. This can be a lengthy and time-consuming process, especially when operating at the cutting edge of diagnostic and life science consumable manufacturing.
  • Production Flexibility: It is difficult to predict sales forecasts in the early years, the unfortunate reality is it always takes longer than expected to gain a significant market share. Creating a manufacturing line that is misaligned with demand can massively increase piece-price costs due to underutilized labor and exaggerated overheads. SCHOTT MINIFAB affords our clients flexibility when it comes to production volumes enabling our clients to get product on the market with minimal investment and build confidence in sales volumes. This means when investing in expensive high throughput automation equipment, there is high confidence on the return on investment.

The piece-price at low volumes is too high: Piece price at low volumes is going to be higher than at high volumes due to the manual / semi-automated nature of the processes, however the investment needed to produce these parts is significantly lower as our clients are leveraging our Pilot Line capability.

  • This could mean anywhere from the first 100s of thousands of units require less overall investment and take less time. This allows our clients' Sales and Marketing teams to get products in users hands fast and develop robust demand forecasts before larger investments are made to scale up production. This is when piece prices will be more in line with expectations.

Smart investment, partnering with a trusted expert

Business leaders in diagnostic and life science companies are faced with a difficult decision when it comes to deciding how their product gets made. By focusing on core competencies, reducing capital investments, and enjoying production flexibility, businesses can navigate the challenging journey from development to product launch more efficiently by partnering with SCHOTT MINIFAB.

Addressing the initial concerns about costs through a comprehensive understanding of the overall expenditure makes this approach not just financially viable but also a smart investment in the future of the company.

If you are looking for more information about the development and manufacture of microfluidic and microarray products for life science and diagnostics, please feel free to reach out to me. I would enjoy learning more about your business and if SCHOTT MINIFAB can help you achieve your goals.

Unlocking Success: Navigating Unknowns in Microfluidic Product Development

Webinar Replay - Unlocking Success: Navigating Unknowns in Microfluidic Product Development

Dr. Briony Cristiano, Head of Bioscience at SCHOTT MINIFAB, sheds light on how to navigate unknowns in microfluidic product development.

In this free webinar, she and host Dr. James Downs focus on six areas of the development path, from product vision to commercialization. As an innovator, you can gain insights on how to overcome technical challenges and reduce risk. These key learnings are offered to help you maximize the likelihood of success.

Read more to access the Webinar Replay

Meet the team at AACC 2023

SCHOTT MINIFAB will be exhibiting at the AMERICAN ASSOCIATION OF CLINICAL CHEMISTRY, which will take place in Anaheim, CA from July 23-27.  


Your partner in advancing diagnostics and life sciences.

SCHOTT MINIFAB provides integrated services for contract design, development and manufacturing of diagnostic and life science consumables - innovation to help you introduce new discoveries, enable precise health care treatments and improve patients outcomes. 

SCHOTT Opens First Facility in U.S. to Increase Capabilities and Capacity0 for Development and Manufacturing of Diagnostics and Life Sciences Products

SCHOTT Opens First Facility in U.S. to Increase Capabilities and Capacity for Development and Manufacturing of Diagnostics and Life Sciences Products

Being committed to continued advances in improving human health, SCHOTT has opened a new facility in Phoenix, Arizona, to expand the development and manufacturing of diagnostics and life science consumables. Launching the first fully integrated microfluidic foundry in the United States validates SCHOTT’s global growth plan and increases production capabilities to help get these products to market faster and more efficiently.

Web Seminar Replay: Point-of-care diagnostics design, development and manufacturing. When outsourcing makes sense.

Watch Webinar Replay: Thursday, March 10th 2022 @ 11:00AM AEDT

This webinar will examine these challenges and explore which key decision-making factors are important when considering an in-house effort vs outsourcing to a partner. In this presentation, Andrew Campitelli will address these issues with the goal of helping diagnostic stakeholders make better decisions toward the growth of their diagnostic programs.


Nine Critical Factors to Diagnostic Microarray Development. 20 Years of Lessons Learned.


The successful design and development of medical diagnostic point of care or clinical microarrays can be among the most daunting of challenges for both startups and incumbent companies alike.  Navigating this challenging path requires significant experience and multidisciplinary expertise.  With an introduction from SCHOTT MINIFAB’s Dr. James Downs, in this 30-minute presentation, Dr. Tamma Kaysser-Kranich will discuss 9 key factors critical to diagnostic microarray development for the IVD market.


The webinar had some buffering issues effecting the audio capture.  Click here for a pre-recorded session.

New Microarray Development & Manufacture Capabilities: Watch Free Live Session

Speaker: Tamma M. Kaysser-Kranich, Ph.D.
VP, Chief Technology Officer, Applied Microarrays

Recorded: Lab-on-Chip & Microfluidics Congress, Coronado CA

I'll cover two main topics in this talk. I’ll spend a little bit of time introducing Applied Microarrays, in case you are not familiar with our capabilities. I’ll go also some the exciting evolution in our own business in becoming part of SCHOTT MINIFAB and what that means for what we can offer to IVD design development and manufacturing. 

Watch Free Web Session: Deep Dive Into Microfluidics Manufacturing and Microarrays

Watch Free Web Session
LIVE recorded on Wednesday, November 10th 2021

Join leading experts in microfluidic polymer and glass diagnostics for this deep dive into microfluidic diagnostics development. The two sessions blend commercial and technical subjects across IVD manufacturing and microarray development.

Pre-scored Glass Wafer Lowering the Cost of Biochips

Whether you are developing a glass biochip for inhouse use, or as a commercial product, cost-of-good (COGs) has always been at the top of consideration list. Key to managing COGs is the ability to keep costs as low as possible in small quantities whilst still taking advantage of economy of scale as demand increases. This is particularly challenging with customized glass chips.